Company news: Eli Lilly and Boehringer Ingelheim

Share this article:
Eli Lilly will pay Boehringer Ingelheim $387.4 million as part of a deal to jointly develop and commercialize several diabetes pipeline agents. Products covered under the pact include two oral agents from BI—DPP-4 inhibitor linagliptin, filed with the FDA, and SGLT-2 inhibitor BI10773, in Phase III—and two basal insulin analogues from Lilly which will enter Phase III this year, plus an option on Lilly's anti-TGF-beta monoclonal antibody. The firms will split revenues from any approved drugs, and the deal includes milestone payments -- up to $1 million for Lilly and up to  $807 million for BI. “This deal should inject some life into [Lilly's] diabetes franchise, which has been losing share,” wrote Credit-Suisse analyst Catherine Arnold in an investor note today.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.